Orladeyo
Hereditary angioedema
CommercialActive
Key Facts
About Royalty Pharma
Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.
View full company profileOther Hereditary angioedema Drugs
| Drug | Company | Phase |
|---|---|---|
| CSL312 | CSL | Phase 3 |
| DAWNZERA (donidalorsen) | Ionis Pharmaceuticals | Phase 3 |